Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04065373 · ClinicalTrials.gov registry record · NA
ivWatch SmartTouch Sensor: Device Validation for Non-Infiltrated Tissues
A NA study, sponsored by ivWatch.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT04065373: Completed NA study, sponsored by ivWatch.
NCT04065373 is a NA study that has completed, run by ivWatch. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04065373, a NA study, has completed, sponsored by ivWatch.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
A single arm study of 40 adult volunteers to assess the safety and efficacy of the ivWatch SmartTouch and fiber optic sensors when observing non-infiltrated (normal) tissues at common peripheral IV therapy sites.
Primary Outcome
The ivWatch Model 400 issues red notifications to communicate the need for a clinician to check an IV site. A red notification suggests an increased likelihood that an IV infiltration may be occurring, with a greater likelihood relative to a yellow notification. This measure describes the average number of red notifications issued by the ivWatch device in a given day when monitoring normal, non-infiltrated tissues. The 95% confidence interval for the red notification rate was calculated using a
Interventions
- DEVICE ivWatch Model 400 with SmartTouch and fiber optic sensor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2019-04-25 |
| Est. Completion | 2019-06-21 |
| Phase | NA |
What the finished NCT04065373 record still lists
NCT04065373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which ivWatch Model 400 with SmartTouch and fiber optic sensor is the first listed.
NCT04065373 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04065373 about?
NCT04065373 is a clinical study titled "ivWatch SmartTouch Sensor: Device Validation for Non-Infiltrated Tissues". A single arm study of 40 adult volunteers to assess the safety and efficacy of the ivWatch SmartTouch and fiber optic sensors when observing non-infiltrated (normal) tissues at common peripheral IV therapy sites.
What is the current status of trial NCT04065373?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2019-04-25. Estimated completion is 2019-06-21.
What interventions are being tested in trial NCT04065373?
The interventions under investigation include: ivWatch Model 400 with SmartTouch and fiber optic sensor (DEVICE).
Who is sponsoring clinical trial NCT04065373?
This trial is sponsored by ivWatch, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04065373's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI